This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liu, P. Y. Articles by Handelsman, D. J. Search for Related Content PubMed PubMed Citation Articles by Liu, P. Y. Articles by Handelsman, D. J. Pubmed/NCBI databases Substance via MeSH Hazardous Substances DB CHORIONIC GONADOTROPIN Medline Plus Health Information Seniors' Health

A Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Recombinant Human Chorionic Gonadotropin on Muscle Strength and Physical Function and Activity in Older Men with Partial Age-Related Androgen Deficiency

Department of Andrology, Concord Hospital and ANZAC Research Institute, University of Sydney, Concord NSW 2139, Australia

Address all correspondence and requests for reprints to: Prof. D. J. Handelsman, ANZAC Research Institute, Concord, New South Wales 2139, Australia. E-mail: . djh{at}med.usyd.edu.au

Abstract

Despite partial androgen deficiency, the safety and efficacy of androgen therapy in older men remains controversial because controlled studies of testosterone have given equivocal results. Human chorionic gonadotropin (hCG) can be conveniently and infrequently self-administered, and it increases not only circulating testosterone but also estradiol and other testicular steroids. We evaluated the efficacy and safety of 3 months of treatment with sc recombinant hCG (r-hCG, Ovidrel) on muscle mass, strength, mobility, and physical activity in ambulant, community-dwelling men more than 60 yr old having partial androgen deficiency (testosterone 15 nmol/liter, twice). Forty eligible men (mean age, 67 yr; range, 60–85 yr) were randomized to receive r-hCG (5000 IU, 250 µg) or placebo by twice weekly sc self-injection and were studied before treatment, monthly during treatment, and 1 month after treatment. All completed the study, and treatment groups were well matched. r-hCG significantly increased body weight (1 kg; P < 0.05) and lean body mass (2 kg; P < 0.001) and reduced fat mass (1 kg, P < 0.05). However, anthropometric measures of skinfold thickness (biceps, triceps, subscapular, suprailiac) and circumferences (midarm, waist, hip, and midthigh), including the waist-hip ratio, did not change significantly. Shoulder and knee strength (peak torque), as measured by isokinetic and isometric dynamometry, was not significantly increased, nor was physical activity (accelerometry and Physical Activity Scale for Elderly self-report) or gait and balance (modified Guralnik and Frailty and Injuries: Cooperative Studies of Intervention Techniques performance batteries) altered. Total and free testosterone and estradiol were markedly (150%; P < 0.001) and stably increased, whereas LH, FSH, and urea were significantly decreased. Testis volume was significantly decreased (5 ml; P < 0.05). There were no significant changes in hemoglobin, osteocalcin, or prostate-specific antigen, and the International Prostate Symptom Score did not change. Three men developed nipple tenderness that did not progress to gynecomastia. We conclude that 3 months of treatment with twice weekly r-hCG demonstrates sustained androgenic effects on hormones and muscle mass but has no effect on muscle strength or physical functioning.

This article has been cited by other articles:

				T. E. Patterson, K. Kumagai, L. Griffith, and G. F. Muschler Cellular Strategies for Enhancement of Fracture Repair J. Bone Joint Surg. Am., February 1, 2008; 90(Supplement_1): 111 - 119. [Abstract] [Full Text] [PDF]

				P. Y. Liu, P. Y. Takahashi, P. D. Roebuck, and J. D. Veldhuis Age or Factors Associated with Aging Attenuate Testosterone's Concentration-Dependent Enhancement of the Regularity of Luteinizing Hormone Secretion in Healthy Men J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 4077 - 4084. [Abstract] [Full Text] [PDF]

				D. J. Handelsman The Rationale for Banning Human Chorionic Gonadotropin and Estrogen Blockers in Sport J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1646 - 1653. [Abstract] [Full Text] [PDF]

				P. Y. Liu, S. M. Pincus, P. Y. Takahashi, P. D. Roebuck, A. Iranmanesh, D. M. Keenan, and J. D. Veldhuis Aging attenuates both the regularity and joint synchrony of LH and testosterone secretion in normal men: analyses via a model of graded GnRH receptor blockade Am J Physiol Endocrinol Metab, January 1, 2006; 290(1): E34 - E41. [Abstract] [Full Text] [PDF]

				J. M. Kaufman and A. Vermeulen The Decline of Androgen Levels in Elderly Men and Its Clinical and Therapeutic Implications Endocr. Rev., October 1, 2005; 26(6): 833 - 876. [Abstract] [Full Text] [PDF]

				P. Y. Takahashi, P. Y. Liu, P. D. Roebuck, A. Iranmanesh, and J. D. Veldhuis Graded Inhibition of Pulsatile Luteinizing Hormone Secretion by a Selective Gonadotropin-Releasing Hormone (GnRH)-Receptor Antagonist in Healthy Men: Evidence That Age Attenuates Hypothalamic GnRH Outflow J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2768 - 2774. [Abstract] [Full Text] [PDF]

				P. Y. Liu, S. M. Pincus, D. M. Keenan, F. Roelfsema, and J. D. Veldhuis Analysis of bidirectional pattern synchrony of concentration-secretion pairs: implementation in the human testicular and adrenal axes Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2005; 288(2): R440 - R446. [Abstract] [Full Text] [PDF]

				P. Y. Liu, R. S. Swerdloff, and J. D. Veldhuis The Rationale, Efficacy and Safety of Androgen Therapy in Older Men: Future Research and Current Practice Recommendations J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 4789 - 4796. [Abstract] [Full Text] [PDF]

				G. F. Muschler, C. Nakamoto, and L. G. Griffith Engineering Principles of Clinical Cell-Based Tissue Engineering J. Bone Joint Surg. Am., July 1, 2004; 86(7): 1541 - 1558. [Abstract] [Full Text] [PDF]

				C. Meier, P. Y. Liu, L. P. Ly, J. de Winter-Modzelewski, M. Jimenez, D. J. Handelsman, and M. J. Seibel Recombinant Human Chorionic Gonadotropin But Not Dihydrotestosterone Alone Stimulates Osteoblastic Collagen Synthesis in Older Men with Partial Age-Related Androgen Deficiency J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 3033 - 3041. [Abstract] [Full Text] [PDF]

				P. Y. Liu, B. Yee, S. M. Wishart, M. Jimenez, D. G. Jung, R. R. Grunstein, and D. J. Handelsman The Short-Term Effects of High-Dose Testosterone on Sleep, Breathing, and Function in Older Men J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3605 - 3613. [Abstract] [Full Text] [PDF]